RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MRNA therapy takes on Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests a new mRNA medicine called mRNA-2808 in people whose multiple myeloma has returned or stopped responding to standard treatments. The goal is to see if the treatment is safe and can shrink or control the cancer. About 166 participants will receive the drug, and re…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New hope for tough myeloma: YKST02 trial launches
Disease control Recruiting nowThis early-stage trial tests a new medicine, YKST02, in about 70 people whose multiple myeloma has returned or not responded to at least two prior treatments. The drug is designed to help the body's immune system fight the cancer. The main goals are to check safety and find the r…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 17, 2026 04:11 UTC
-
New Triple-Action antibody takes on tough blood cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells from multiple angles. It is for people with relapsed or refractory multiple myeloma or AL amyloidosis who have tried other treatments. The main goals are …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 17, 2026 04:08 UTC
-
New hope for myeloma: experimental combo aims to outperform standard care
Disease control Recruiting nowThis study tests a new drug combination (mezigdomide, bortezomib, and dexamethasone) against a standard combination (pomalidomide, bortezomib, and dexamethasone) in about 810 people with multiple myeloma that has returned or stopped responding to treatment. Participants must have…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 17, 2026 04:08 UTC
-
New Dual-Target CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests a new treatment called O&D-001 for people with multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR T cells) that target two proteins on myeloma cells: BCMA and GPRC5…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: O&D BioTech Group CO., Limited • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo aims to beat back hard-to-treat blood cancer
Disease control Recruiting nowThis study tests a new drug called QLS32015 combined with other cancer medicines in 160 people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if these combinations can shrink tumors or make cancer undetectable. Participants will …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New Triple-Action antibody takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial tests a new drug called SIM0500 in about 130 adults with multiple myeloma that has come back or stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells from three different angles. The main goal is to ch…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for hard-to-treat myeloma: experimental drug enters final testing phase
Disease control Recruiting nowThis study tests a new drug called QLS32015 against two standard treatments (pomalidomide with dexamethasone, or selinexor with dexamethasone) in 228 adults with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if QLS32015 alone c…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug duo takes on Tough-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and effective for people with multiple myeloma that has returned or stopped responding to prior therapies. About 120 participants will receive the drug combination to find the best …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for Hard-to-Treat myeloma: first human trial launches
Disease control Recruiting nowThis early-phase study tests an experimental drug called JNJ-87562761 in people with multiple myeloma whose cancer has returned or stopped responding to prior treatments. The main goals are to find a safe dose and check for side effects. About 80 participants will take part in th…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for hard-to-treat myeloma: experimental combo shows promise
Disease control Recruiting nowThis study tests a new drug, F182112, given with other treatments for people whose multiple myeloma has returned or stopped responding to prior therapy. About 90 participants will receive the combination to see if it shrinks tumors and how safe it is. The goal is to control the d…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated May 11, 2026 20:53 UTC